The positive results from the Phase 2/3 study of a higher dose of nusinersen indicate a significant improvement in motor function for infants with SMA. This development is crucial for Biogen as it enhances the therapeutic profile of nusinersen, potentially leading to increased adoption and sales. The news is likely to be well-received by investors, leading to a positive impact on Biogen's stock price in the short term.